Immune enhancement of N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan nanoparticles vaccine

Gao, Yuan; Gong, Xiaochen; Yu, Shuang; Jin, Zheng; Ruan, Qicheng; Zhang, Chunjing; Zhao, Kai

doi:10.1016/j.ijbiomac.2022.08.073

Cited by 19 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that the expression of pro-inflammatory cytokines (IL-6, IL-4, etc.) in mice increased significantly after the nano-drug treatment, which indicated that the nano-system could effectively promote the occurrence of immune response ( Gao et al, 2022 ).…”

Section: Main Treatment Methodsmentioning

confidence: 99%

Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

Liu,

Gao,

Miao

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

The global prevalence of Helicobacter pylori (H. pylori) infection remains high, indicating a persistent presence of this pathogenic bacterium capable of infecting humans. This review summarizes the population demographics, transmission routes, as well as conventional and novel therapeutic approaches for H. pylori infection. The prevalence of H. pylori infection exceeds 30% in numerous countries worldwide and can be transmitted through interpersonal and zoonotic routes. Cytotoxin-related gene A (CagA) and vacuolar cytotoxin A (VacA) are the main virulence factors of H. pylori, contributing to its steep global infection rate. Preventative measures should be taken from people’s living habits and dietary factors to reduce H. pylori infection. Phytotherapy, probiotics therapies and some emerging therapies have emerged as alternative treatments for H. pylori infection, addressing the issue of elevated antibiotic resistance rates. Plant extracts primarily target urease activity and adhesion activity to treat H. pylori, while probiotics prevent H. pylori infection through both immune and non-immune pathways. In the future, the primary research focus will be on combining multiple treatment methods to effectively eradicate H. pylori infection.

show abstract

Section: Main Treatment Methodsmentioning

confidence: 99%

Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

Liu,

Gao,

Miao

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Chitosan Derivative-Based Nanoparticles. Among the various chitosan derivatives, carboxymethyl CS, 87 trimethyl CS, 88 thiolated CS, 89 and PEGylated CS 90 have been extensively investigated in the recent past. Several techniques were employed to synthesize NPs containing chitosan derivatives.…”

Section: Chitosan Derivative-based Nanocarriersmentioning

confidence: 99%

“…The intramuscular administration of the prepared NPs resulted in higher immunoglobulin production in mice. 87 5.2. Chitosan Derivative-Based Nanofibers.…”

Section: Chitosan Derivative-based Nanocarriersmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan Derivatives as Carriers for Drug Delivery and Biomedical Applications

Manna

Seth

Gupta

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Over the past few decades, chitosan (CS) has gained the attention of researchers investigating newer biomaterial-based carriers for drugs in pharmaceutical and biomedical research. Combined with its nontoxic behavior, biodegradability, and biocompatibility, chitosan has found widespread applications in the fields of drug delivery, tissue engineering, and cosmetics. As a novel drug carrier, chitosan is regarded as one of the promising biomaterials in the pharmaceutical industry. The extensive use of this cationic biopolysaccharide in the delivery of therapeutic agents has brought a few limitations of chitosan into the limelight. Various chemical modifications of chitosan can minimize these limitations and improve the efficacy of chitosan as a drug carrier. The effectiveness of several chemically modified chitosan derivatives, including trimethyl chitosan, thiolated chitosan, PEGylated chitosan, and other chitosan derivatives, has been investigated by many researchers for the controlled and target specific delivery of therapeutics. The chemically modified chitosan derivatives exhibited greater importance in the current scenario on drug delivery due to their solubility in wide range of media along with their interaction with pharmaceutically active ingredients. Chitosan derivatives have also attracted attention in several biomedical fields, including wound healing, hyperthermia therapy, tissue engineering, and bioadhesives. The present review narrates the sources and common physicochemical properties of chitosan, including several important synthetic modifications to obtain chemically modified chitosans and their applications in targetspecific drug delivery, along with several biomedical applications.

show abstract

“…Unfortunately, the poor solubility and the restricted drug-loading efficiency of native chitosan limit its applications in biomedical research. By modifying the structure of chitosan with hydrophilic groups, the solubility and the physicochemical properties of chitosan are greatly improved. − Nanoparticles prepared based on these chitosan derivatives further enhance the adsorption of antigen vaccines at the mucosal site and promote the uptake efficiency of vaccines by cells, broadening the usage of chitosan in the field of vaccine research. , Current studies mainly focus on the effective preparation of nano-carriers and the optimization of parametric properties, while the immunomodulatory function of nano-carriers themselves is still in the early research stage.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Immune Responses to Mucosa by Functionalized Chitosan-Based Composite Nanoparticles as a Vaccine Adjuvant for Intranasal Delivery

Lin

Sun

Jin

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Nasal administration for vaccine delivery is a novel non-invasive vaccine administration approach that can induce local or systemic immune responses and overcome the disadvantages caused by traditional injectable administration. However, mucosal vaccine and adjuvant delivery systems with sustained-release ability and enhanced immune effects at mucosal sites have still been highly demanded. In this work, N-2-hydroxypropyl trimethyl ammonium chloride chitosan/N,O-carboxymethyl chitosan nanoparticles (N-2-HACC/CMCS NPs) with excellent mucosal absorption, high drug loading capacity, and enhanced immune responses were prepared by the ionic cross-linking method. To evaluate the potential capacity of the N-2-HACC/CMCS NPs as a vaccine adjuvant and the molecular mechanism for the induction of enhanced mucosal and systemic immune responses, bovine serum albumin (BSA) was employed as a general model antigen and loaded into the N-2-HACC/CMCS NPs to prepare a BSA-loaded N-2-HACC/CMCS adjuvant vaccine (N-2-HACC/CMCS/BSA NPs). It was well demonstrated that the N-2-HACC/CMCS/BSA NPs with great biostability and mucosal absorption could effectively promote the proliferation of lymphocytes and the secretion of related pro-inflammatory factors, resulting in the stimulation of specific mucosal and systemic immune responses. This study revealed that the chitosan-based nano-delivery system can act as the mucosal vaccine adjuvant and possesses great promise in viral infectious diseases and immunization therapy.

show abstract

Immune enhancement of N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan nanoparticles vaccine

Cited by 19 publications

References 46 publications

Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

Chitosan Derivatives as Carriers for Drug Delivery and Biomedical Applications

Enhanced Immune Responses to Mucosa by Functionalized Chitosan-Based Composite Nanoparticles as a Vaccine Adjuvant for Intranasal Delivery

Contact Info

Product

Resources

About